Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Advanced Drainage Systems Announces Fourth Quarter and Fiscal 2019 Results

Published

on

Reading Time: 13 minutes

HILLIARD, Ohio–(BUSINESS WIRE)–Advanced Drainage Systems, Inc. (NYSE: WMS) (“ADS” or the “Company”), a
leading global manufacturer of water management products and solutions
for non-residential, residential, infrastructure and agricultural
applications, today announced financial results for the fourth quarter
and fiscal year ended March 31, 2019.

Fourth Quarter Fiscal 2019 Results

  • Net sales increased 8.8% to $272.2 million
  • Net income increased 139.0% to $1.9 million
  • Adjusted EBITDA (Non-GAAP) increased 36.5% to $36.9 million

Fiscal 2019 Results

  • Net sales increased 4.1% to $1,384.7 million
  • Net income increased 25.8% to $81.5 million
  • Adjusted EBITDA (Non-GAAP) increased 10.3% to $232.0 million
  • Cash provided by operating activities increased 10.6% to $151.7
    million
  • Free cash flow (Non-GAAP) increased 13.5% to $108.3 million

Scott Barbour, President and Chief Executive Officer of ADS commented,
“We closed out another strong year by achieving fourth quarter top and
bottom-line results, driven by disciplined execution of our market share
model and conversion strategy. The strength in our fourth quarter
results reflect increased volume across our key geographies for both
Pipe and Allied products, favorable pricing and operational efficiency
in manufacturing and transportation.”

Barbour continued, “Our commitment to continuous improvement and
best-in-class water management solutions propelled us to outperform our
core domestic construction markets by approximately 400 basis points in
fiscal 2019 and grow our share in the storm water market. In addition,
we delivered margin expansion of 100 basis points for the year driven by
price attainment, Allied product growth as well as disciplined execution
and cost containment. Looking ahead to fiscal 2020, we will continue to
deliver on our three-year plan to increase shareholder value by
capitalizing on our leadership position and strength in our end markets
to drive growth, while achieving sustained profitability and maintaining
a strong balance sheet.”

Fourth Quarter Fiscal 2019 Results

Net sales increased 8.8% to $272.2 million, as compared to $250.1
million in the prior year. Domestic net sales increased 11.1% to $251.2
million as compared to $226.2 million in the prior year, driven by a
12.8% increase in construction market sales. International net sales
decreased 12.1% to $21.0 million as compared to $23.9 million in the
prior year, driven primarily by a decrease in Mexico sales.

Gross profit increased 23.7% to $59.5 million, as compared to $48.1
million the prior year quarter. As a percentage of net sales, gross
profit increased 270 basis points to 21.9%, compared to 19.2% in the
prior year. The margin expansion is primarily due to an increase in
volume, favorable pricing and successful cost containment efforts.

Adjusted EBITDA (Non-GAAP) increased 36.5% to $36.9 million, as compared
to $27.0 million in the prior year quarter. As a percentage of net
sales, Adjusted EBITDA increased 270 basis points to 13.5% as compared
to 10.8% in the prior year. The increase in Adjusted EBITDA margin was
largely attributed to the factors mentioned above.

Reconciliations of GAAP to Non-GAAP financial measures for Adjusted
EBITDA and Free Cash Flow have been provided in the financial statement
tables included in this press release. An explanation of these measures
is also included below under the heading “Non-GAAP Financial Measures.”

Fiscal 2019 Results

Net sales increased 4.1% to $1,384.7 million, as compared to $1,330.4
million in the prior year. Domestic net sales increased 4.2% to $1,224.1
million, as compared to $1,174.4 million in the prior year, primarily
driven by solid construction market demand, favorable pricing and strong
Allied product sales. International net sales increased 2.9% to $160.6
million, as compared to $155.9 million in the prior year, driven
primarily by growth in our Exports business.

Gross profit increased 8.1% to $327.0 million, as compared to $302.5
million the prior year. As a percentage of net sales, gross profit
increased 90 basis points to 23.6%, compared to 22.7% in the prior year.
The margin increase is primarily due to favorable pricing and successful
cost containment efforts, partially offset by higher inflationary costs
on resin, transportation and wages, among others.

Adjusted EBITDA (Non-GAAP) increased 10.3% to $232.0 million, as
compared to $210.2 million in the prior year. As a percentage of net
sales, Adjusted EBITDA increased 100 basis points to 16.8% as compared
to 15.8% in the prior year. The increase in Adjusted EBITDA margin was
largely attributed to the factors mentioned above.

Net cash from operating activities increased 10.6% to $151.7 million, as
compared to $137.1 million in the prior year. Free cash flow (Non-GAAP)
increased 13.5% to $108.3 million, as compared to $95.4 million in the
prior year. Net debt (total debt and capital lease obligations net of
cash) was $310.3 million as of March 31, 2019, a decrease of $51.8
million from March 31, 2018.

Fiscal 2020 Outlook

Based on current visibility, backlog of existing orders and business
trends, the Company has provided its net sales and Adjusted EBITDA
targets for fiscal 2020. Net sales are expected to be in the range of
$1.425 billion to $1.475 billion and Adjusted EBITDA is expected to be
in the range of $245 to $265 million. Capital expenditures are expected
to be in the range of $55 million to $65 million.

Webcast Information

The Company will host an investor conference call and webcast on
Thursday, May 23, 2019 at 10:00 a.m. Eastern Time. The live call can be
accessed by dialing 1-844-484-0244 (US toll-free) or 1-647-689-5142
(international) and asking to be connected to the Advanced Drainage
Systems, Inc. call. The live webcast will also be accessible via the
“Events Calendar” section of the Company’s Investor Relations website, www.investors.ads-pipe.com.
An archived version of the webcast will be available for one year
following the call.

About the Company

Advanced Drainage Systems is the leading manufacturer of high
performance thermoplastic corrugated pipe, providing a comprehensive
suite of water management products and superior drainage solutions for
use in the construction and infrastructure marketplace. Its innovative
products are used across a broad range of end markets and applications,
including non-residential, residential, agriculture and infrastructure
applications. The Company has established a leading position in many of
these end markets by leveraging its national sales and distribution
platform, overall product breadth and scale and manufacturing
excellence. Founded in 1966, the Company operates a global network of
approximately 55 manufacturing plants and over 30 distribution centers.
To learn more about ADS, please visit the Company’s website at www.ads-pipe.com.

Forward Looking Statements

Certain statements in this press release may be deemed to be
forward-looking statements. These statements are not historical facts
but rather are based on the Company’s current expectations, estimates
and projections regarding the Company’s business, operations and other
factors relating thereto. Words such as “may,” “will,” “could,” “would,”
“should,” “anticipate,” “predict,” “potential,” “continue,” “expects,”
“intends,” “plans,” “projects,” “believes,” “estimates,” “confident” and
similar expressions are used to identify these forward-looking
statements. Factors that could cause actual results to differ from those
reflected in forward-looking statements relating to our operations and
business include: fluctuations in the price and availability of resins
and other raw materials and our ability to pass any increased costs of
raw materials on to our customers in a timely manner; volatility in
general business and economic conditions in the markets in which we
operate, including, without limitation, factors relating to availability
of credit, interest rates, fluctuations in capital and business and
consumer confidence; cyclicality and seasonality of the non-residential
and residential construction markets and infrastructure spending; the
risks of increasing competition in our existing and future markets,
including competition from both manufacturers of high performance
thermoplastic corrugated pipe and manufacturers of products using
alternative materials; our ability to continue to convert current demand
for concrete, steel and PVC pipe products into demand for our high
performance thermoplastic corrugated pipe and Allied Products; the
effect of weather or seasonality; the loss of any of our significant
customers; the risks of doing business internationally; the risks of
conducting a portion of our operations through joint ventures; our
ability to expand into new geographic or product markets; our ability to
achieve the acquisition component of our growth strategy; the risk
associated with manufacturing processes; our ability to manage our
assets; the risks associated with our product warranties; our ability to
manage our supply purchasing and customer credit policies; the risks
associated with our self-insured programs; our ability to control labor
costs and to attract, train and retain highly-qualified employees and
key personnel; our ability to protect our intellectual property rights;
changes in laws and regulations, including environmental laws and
regulations; our ability to project product mix; the risks associated
with our current levels of indebtedness; fluctuations in our effective
tax rate, including from the recently enacted Tax Cuts and Jobs Act;
changes to our operating results, cash flows and financial condition
attributable to the recently enacted Tax Cuts and Jobs Act; our ability
to meet future capital requirements and fund our liquidity needs; the
risk that additional information may arise that would require the
Company to make additional adjustments or revisions or to restate the
financial statements and other financial data for certain prior periods
and any future periods, any delay in the filing of any filings with the
Securities and Exchange Commission (“SEC”); the review of potential
weaknesses or deficiencies in the Company’s disclosure controls and
procedures, and discovering weaknesses of which we are not currently
aware or which have not been detected and the other risks and
uncertainties described in the Company’s filings with the SEC. New risks
and uncertainties emerge from time to time and it is not possible for
the Company to predict all risks and uncertainties that could have an
impact on the forward-looking statements contained in this press
release. In light of the significant uncertainties inherent in the
forward-looking information included herein, the inclusion of such
information should not be regarded as a representation by the Company or
any other person that the Company’s expectations, objectives or plans
will be achieved in the timeframe anticipated or at all. Investors are
cautioned not to place undue reliance on the Company’s forward-looking
statements and the Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.

Financial Statements

 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
 
  Three Months Ended   Fiscal Year Ended
March 31, March 31,
(Amounts in thousands, except per share data) 2019   2018 2019   2018
Net sales $ 272,218 $ 250,114 $ 1,384,733 $ 1,330,354
Cost of goods sold   212,714   201,999   1,057,766   1,027,873
Gross profit 59,504 48,115 326,967 302,481
Operating expenses:
Selling 24,179 22,416 96,335 92,764
General and administrative 24,610 24,041 89,692 98,392

Loss on disposal of assets and costs from exit and disposal
activities

2,075 4,535 3,647 15,003
Intangible amortization   1,935   1,997   7,880   8,068
Income from operations 6,705 (4,874 ) 129,413 88,254
Other expense:
Interest expense 4,590 2,642 18,618 15,262
Derivative loss (gains) and other expense (income), net   (729 )   506   (815 )   (3,950 )
Income before income taxes 2,844 (8,022 ) 111,610 76,942
Income tax expense (benefit) 1,081 (4,401 ) 30,049 11,411
Equity in net (income) loss of unconsolidated affiliates   (130 )   1,235   95   739
Net income 1,893 (4,856 ) 81,466 64,792
Less: net income attributable to noncontrolling interest   883   847   3,694   2,785
Net income attributable to ADS 1,010 (5,703 ) 77,772 62,007
Dividends to redeemable convertible preferred stockholders (497 ) (443 ) (2,047 ) (1,858 )
Dividends paid to unvested restricted stockholders   (13 )   (2 )   (69 )   (49 )

Net income available to common stockholders and participating
securities

500 (6,148 ) 75,656 60,100

Undistributed income allocated to participating securities

      (5,474 )   (4,514 )
Net income available to common stockholders $ 500 $ (6,148 ) $ 70,182 $ 55,586
 
Weighted average common shares outstanding:
Basic 57,325 56,302 57,025 55,696
Diluted 57,823 56,302 57,611 56,334
Net income per share:
Basic $ 0.01 $ (0.11 ) $ 1.23 $ 1.00
Diluted $ 0.01 $ (0.11 ) $ 1.22 $ 0.99
Cash dividends declared per share $ 0.08 $ 0.07 $ 0.32 $ 0.28
 
 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
 
  As of
(Amounts in thousands) March 31, 2019   March 31, 2018
ASSETS
Current assets:
Cash $ 8,891 $ 17,587
Receivables, net 186,991 171,961
Inventories 264,540 263,792
Other current assets   6,091   5,113
Total current assets 466,513 458,453
Property, plant and equipment, net 398,891 399,381
Other assets:
Goodwill 102,638 103,017
Intangible assets, net 37,177 44,437
Other assets   36,940   37,954
Total assets $ 1,042,159 $ 1,043,242
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of debt obligations $ 25,932 $ 26,848
Current maturities of capital lease obligations 23,117 22,007
Accounts payable 93,577 105,521
Other accrued liabilities 61,901 60,560
Accrued income taxes   1,758   6,307
Total current liabilities 206,285 221,243
Long-term debt obligations, net 208,602 270,900
Long-term capital lease obligations 61,555 59,963
Deferred tax liabilities 45,963 32,304
Other liabilities   19,119   25,023
Total liabilities 541,524 609,433
Mezzanine equity:
Redeemable convertible preferred stock 282,638 291,247
Deferred compensation — unearned ESOP shares (180,316 ) (190,168 )
Redeemable noncontrolling interest in subsidiaries     8,471
Total mezzanine equity 102,322 109,550
Stockholders’ equity:
Common stock 11,436 11,426
Paid-in capital 391,039 364,908
Common stock in treasury, at cost (9,863 ) (8,277 )
Accumulated other comprehensive loss (25,867 ) (21,247 )
Retained earnings (deficit)   17,582   (39,214 )
Total ADS stockholders’ equity 384,327 307,596
Noncontrolling interest in subsidiaries   13,986   16,663
Total stockholders’ equity   398,313   324,259
Total liabilities, mezzanine equity and stockholders’ equity $ 1,042,159 $ 1,043,242
 
 
ADVANCED DRAINAGE SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
  Fiscal Year Ended March 31,
(Amounts in thousands) 2019   2018
Cash Flow from Operating Activities
Net income $ 81,466 $ 64,792
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization 71,900 75,003
Deferred income taxes 12,813 (11,239 )
Loss on disposal of assets and costs from exit and disposal
activities
3,647 12,655
ESOP and stock-based compensation 21,828 18,845
Amortization of deferred financing charges 735 934
Fair market value adjustments to derivatives 2,346 (3,244 )
Equity in net loss (income) of unconsolidated affiliates 95 739
Other operating activities (5,219 ) 1,010
Changes in working capital:
Receivables (17,953 ) (4,327 )
Inventories (2,034 ) (4,841 )
Prepaid expenses and other current assets (1,004 ) 1,648
Accounts payable, accrued expenses, and other liabilities   (16,942 )   (14,855 )
Net cash provided by operating activities 151,678 137,120
Cash Flows from Investing Activities
Capital expenditures (43,412 ) (41,709 )
Cash paid for acquisitions, net of cash acquired (1,990 )
Proceeds from sale of corporate-owned life insurance 13,644
Other investing activities   868   (390 )
Net cash used in investing activities (42,544 ) (30,445 )
Cash Flows from Financing Activities
Proceeds from Revolving Credit Facility 405,700 487,850
Payments on Revolving Credit Facility (442,800 ) (512,150 )
Payments on Term Loan (72,500 )
Proceeds from Senior Notes 75,000
Payments on Senior Notes (25,000 ) (25,000 )
Debt issuance costs (2,268 )
Equipment financing loans (909 )
Payments of notes, mortgages, and other debt (940 ) (1,905 )
Payments on capital lease obligations (24,284 ) (24,214 )
Acquisition of noncontrolling interest in BaySaver (8,800 )
Cash dividends paid (26,148 ) (18,478 )
Proceeds from exercise of stock options 5,908 9,087
Repurchase of common stock (7,947 )
Other financing activities   (382 )   (2,428 )
Net cash provided by financing activities (117,655 ) (94,953 )
Effect of exchange rate changes on cash   (175 )   (585 )
Net change in cash (8,696 ) 11,137
Cash at beginning of period   17,587   6,450
Cash at end of period $ 8,891 $ 17,587
 

Selected Financial Data

The following tables set forth net sales by reportable segment for each
of the periods indicated.

               
Three Months Ended Fiscal Year Ended

(Amounts in thousands
except percentages)

March 31, % March 31, %
2019   2018 Variance 2019  

2018

Variance
Domestic    
Pipe $ 180,780 $ 161,364 12.0 % $ 868,805 $ 844,875 2.8 %
Allied Products   70,405   64,815 8.6 %   355,326   329,557 7.8 %
Domestic net sales $ 251,185 $ 226,179 11.1 % $ 1,224,131 $ 1,174,432 4.2 %
International
Pipe $ 14,800 $ 17,647 (16.1 %) $ 122,836 $ 119,207 3.0 %
Allied Products   6,233   6,288 (0.9 %)   37,766   36,715 2.9 %
International net sales $ 21,033 $ 23,935 (12.1 %) $ 160,602 $ 155,922 3.0 %
Consolidated
Pipe $ 195,580 $ 179,011 9.3 % $ 991,641 $ 964,082 2.9 %
Allied Products   76,638   71,103 7.8 %   393,092   366,272 7.3 %
Net sales $ 272,218 $ 250,114 8.8 % $ 1,384,733 $ 1,330,354 4.1 %
 

Employee Stock Ownership Plan (“ESOP”)

The Company established an ESOP to enable employees to acquire stock
ownership in ADS in the form of redeemable convertible preferred shares
(“preferred shares”). All preferred shares will be converted to common
shares by plan maturity, which will be no later than March 2023. The
ESOP’s conversion of preferred shares into common shares will have a
meaningful impact on net income, net income per share and common shares
outstanding. The common shares outstanding will be greater after
conversion.

Net Income

The impact of the ESOP on net income includes the ESOP deferred
compensation attributable to the preferred shares allocated to employee
accounts during the period, which is a non-cash charge to our earnings
and not deductible for income tax purposes.

   
Three Months Ended Fiscal Year Ended
March 31, March 31,
(Amounts in thousands) 2019     2018 2019     2018
Net income attributable to ADS $ 1,010 $ (5,703 ) $ 77,772 $ 62,007
ESOP deferred compensation 4,183 3,778 15,296 11,724
 

Common shares outstanding

The conversion of the preferred shares will increase the number of
common shares outstanding. Preferred shares will convert to common
shares at plan maturity, or upon retirement, disability, death or vested
terminations over the life of the plan.

Three Months Ended     Fiscal Year Ended
March 31, March 31,
(Shares in thousands) 2019     2018 2019     2018
Weighted average common shares outstanding – Basic   57,325   56,302   57,025   55,696
Conversion of preferred shares 17,460 18,030 17,640 18,298
Unvested restricted shares 43 270 43 270

Non-GAAP Financial Measures

This press release contains financial information determined by methods
other than in accordance with accounting principles generally accepted
in the United States of America (“GAAP”). ADS management uses non-GAAP
measures in its analysis of the Company’s performance. Investors are
encouraged to review the reconciliation of non-GAAP financial measures
to the comparable GAAP results available in the accompanying tables.

Reconciliation of Non-GAAP Financial Measures

This press release includes references to Adjusted EBITDA and Free Cash
Flow, non-GAAP financial measures. These non-GAAP financial measures are
used in addition to and in conjunction with results presented in
accordance with GAAP. These measures are not intended to be substitutes
for those reported in accordance with GAAP. Adjusted EBITDA and Free
Cash Flow may be different from non-GAAP financial measures used by
other companies, even when similar terms are used to identify such
measures.

EBITDA and Adjusted EBITDA are non-GAAP financial measures that comprise
net income before interest, income taxes, depreciation and amortization,
stock-based compensation, non-cash charges and certain other expenses.
The Company’s definition of Adjusted EBITDA may differ from similar
measures used by other companies, even when similar terms are used to
identify such measures. Adjusted EBITDA is a key metric used by
management and the Company’s board of directors to assess financial
performance and evaluate the effectiveness of the Company’s business
strategies. Accordingly, management believes that Adjusted EBITDA
provides useful information to investors and others in understanding and
evaluating our operating results in the same manner as the Company’s
management and board of directors. In order to provide investors with a
meaningful reconciliation, the Company has provided below
reconciliations of Adjusted EBITDA to net income.

Free Cash Flow is a non-GAAP financial measure that comprises cash flow
from operating activities less capital expenditures. Free Cash Flow is a
measure used by management and the Company’s board of directors to
assess the Company’s ability to generate cash. Accordingly, management
believes that Free Cash Flow provides useful information to investors
and others in understanding and evaluating our ability to generate cash
flow from operations after capital expenditures. In order to provide
investors with a meaningful reconciliation, the Company has provided
below a reconciliation of cash flow from operating activities to Free
Cash Flow.

The following tables present a reconciliation of EBITDA and Adjusted
EBITDA to Net Income and Free Cash Flow to Cash Flow from Operating
Activities, the most comparable GAAP measures, for each of the periods
indicated.

Reconciliation of Adjusted EBITDA to Net Income

   
Three Months Ended Fiscal Year Ended
March 31, March 31,
(Amounts in thousands) 2019   2018 2019   2018
Net income $ 1,893 $ (4,856 ) $ 81,466 $ 64,792
Depreciation and amortization 18,988 19,210 71,900 75,003
Interest expense 4,590 2,642 18,618 15,262
Income tax expense (benefit)   1,081   (4,401 )   30,049   11,411
EBITDA 26,552 12,595 202,033 166,468
Derivative fair value adjustments (575 ) 292 634 (443 )
Foreign currency transaction (gains) losses 90 1,130 314 (1,748 )

Loss on disposal of assets and costs from exit and disposal
activities

2,075 4,535 3,647 15,003

Unconsolidated affiliates interest, tax, depreciation and
amortization

226 632 1,463 2,692
Contingent consideration remeasurement 9 6 (6 ) 39
Stock-based compensation expense 1,503 1,981 6,532 7,121
ESOP deferred stock-based compensation 4,183 3,778 15,296 11,724
Executive retirement (benefit) expense 50 491 (178 ) 1,473
Restatement-related (benefit) costs 14 837 (1,924 ) 4,227
Legal settlement 200 2,000
Transaction costs 295 213 699 1,362
Impairment of investment in unconsolidated affiliate 312 312
Strategic growth and operational improvement initiatives   2,440     3,450  
Adjusted EBITDA $ 36,862 $ 27,002 $ 231,960 $ 210,230
 

Contacts

Michael Higgins
VP, Corporate Strategy & Investor Relations
(614)
658-0050
[email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania